• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK publishes 2012 corporate responsibility report

GSK publishes 2012 corporate responsibility report

April 3, 2013
CenterWatch Staff

GlaxoSmithKline has published its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and outlines advances made on this agenda during 2012.

In the report, the company also sets out 23 forward-looking commitments aligned with its core areas of strategic focus including access to medicines, transparency and environmental sustainability. Corporate responsibility is central to GSK’s strategy to deliver sustainable financial performance whilst providing shared value to patients, consumers and governments.

“Operating in a trustworthy and responsible way underpins our business success,” said Sir Andrew Witty, CEO of GSK. “Our record in 2012 shows we are making good progress—taking significant steps to increase clinical data transparency, leading the Access to Medicines Index and doubling funding for our independent research into diseases of the developing world at our Open Lab at Tres Cantos, Spain. We recognize there is more we can do and we will continue to challenge ourselves to find new approaches to create value for both society and shareholders and to improve lives around the world. That is why we are setting out new long-term commitments which will allow those outside the company to track our progress and hold us to account more effectively.”

Setting these new commitments will enable the company to more effectively measure and communicate the progress it makes on this agenda. The report includes commitments to:

  • Continue to work with partners to support the strengthening of healthcare infrastructure which could improve access to healthcare for 20 million under-served people by 2020.
  • Invest in the development of vaccines that do not require continuous refrigeration, making distribution easier and less expensive.
  • Continue to drive a values-based approach to sales and marketing practices across the world, with the interests of consumers and patients at its core.
  • Extend volunteering opportunities for GSK employees to bring about positive change to communities and global health whilst providing individual development.
  • Reduce GSK’s overall carbon footprint by 25% by 2020 (versus 2010) and have a carbon neutral value chain by 2050.

For a full list of commitments in the 2012 Corporate Responsibility report, click here. GSK will begin reporting progress of these new commitments in its next report.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing